ENTRY       D10941                      Drug
NAME        Inotersen sodium (USAN);
            Tegsedi (TN)
PRODUCT     TEGSEDI (Akcea Therapeutics)
FORMULA     C230H299N69O121P19S19. 19Na
EXACT_MASS  7595.7129
MOL_WEIGHT  7600.7669
REMARK      ATC code: N07XX15
            Chemical structure group: DG02693
            Product (DG02693): D10941<US>
EFFICACY    Neuroprotectant, Prealbumin expression inhibitor
  DISEASE   Hereditary transthyretin-mediated amyloidosis [DS:H00845]
  TYPE      Antisense oligonucleotide
COMMENT     Hereditary ATTR amyloidosis treatment
TARGET      TTR [HSA:7276] [KO:K20731] (mRNA)
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             N NERVOUS SYSTEM
              N07 OTHER NERVOUS SYSTEM DRUGS
               N07X OTHER NERVOUS SYSTEM DRUGS
                N07XX Other nervous system drugs
                 N07XX15 Inotersen
                  D10941  Inotersen sodium (USAN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
              Inotersen
               D10941  Inotersen sodium (USAN)
            Target-based classification of drugs [BR:br08310]
             Transporters
              Other transporters
               Others
                TTR
                 D10941  Inotersen sodium (USAN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10941
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10941
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10941
DBLINKS     CAS: 1432726-13-0
            PubChem: 342581795
///
